Andere talen MedRx Co., Ltd

Aandelen

4586

JP3921220004

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 05-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
156 ^JPY	+2,63%		-13,33%	+3,31%

2023	MedRx Co., Ltd rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2023	CI
2019	MedRx Co. Ltd. Rapporteert Geconsolideerde Winstresultaten voor de Negen Maanden Eindigend op 30 September, 2019; Geeft Geconsolideerde Winstrichtlijnen voor het Jaar Eindigend op 31 December, 2019	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MEDRx : Collaboration Partner, Alto Neuroscience, Announces Initiation of Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia	21/06
MedRx : Notice of revised forecasts of consolidated financial results	24/04
MEDRx : Collaboration Partner, Alto Neuroscience, Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia	24/04
MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC	05/02
MedRx Co., Ltd announced that it expects to receive ¥1.9076 million in funding from Evolution Capital Management LLC	11/01
MedRx : Fair Research Inc. Report ( October 12, 2023)	26-10-23
MedRx : Prospect of NDA Re-Submission for MRX-5LBT	10-10-23
MedRx : and Alto Neuroscience Enter Development Agreement for Novel CNS Targeted Medication	25-09-23
MedRx : H1 FY2023 Business Highlight & Financial Results	28-08-23
MedRx : Summary of Business Results for the Second Quarter Ended June 30, 2023 (Consolidated)	18-08-23
MedRx Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	12-05-23
MedRx : Fair Research Inc. Report ( April 10, 2023)	20-04-23
MedRx Co., Ltd announced that it has received ¥1.2272 million in funding from Evolution Capital Management, LLC	24-03-23
MedRx Co., Ltd announced that it expects to receive ¥1.2272 million in funding from Evolution Capital Management, LLC	08-03-23
MedRx : FY2022Business Highlight & Financial Results	02-03-23
MedRx : Fair Research Inc. Report (September 14, 2022)	28-09-22
MedRx : H1 FY2022 Business Highlight & Financial Results	30-08-22
MedRx Co., Ltd announced that it expects to receive ¥3.904 million in funding	22-08-22
MedRx Co., Ltd announced that it has received ¥552.489 million in funding from Macquarie Bank Limited, Investment Arm	03-06-21
MedRx Co., Ltd announced that it expects to receive funding from Macquarie Bank Limited, Investment Arm	18-05-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MedRx Co., Ltd

Aandelen

4586

JP3921220004

Andere talen

Filters